西妥昔单抗联合调强适形放射治疗在局部晚期鼻咽癌患者中的应用价值  

Clinical efficacy of cetuximab combined with IMRT in treatment of patients with locally advanced nasopharyngeal carcinoma

作　　者：彭宗玉 郑飞波[2] 温红[1] 

机构地区：[1]山东省青岛市肿瘤医院,青岛266042 [2]山东省青岛市市立医院核医学科,青岛266011

出　　处：《中国肿瘤临床与康复》2013年第9期993-995,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨西妥昔单抗联合调强适形放射治疗(IMRT)治疗局部晚期鼻咽癌的临床疗效和安全性。方法选择青岛市肿瘤医院收治的100例局部晚期鼻咽癌患者的临床资料,随机分为观察组和对照组,观察组50例患者采用西妥昔单抗联合IMRT治疗,对照组50例患者采用IMRT治疗,比较两组患者的疗效。结果治疗后,观察组患者总有效率为92.0%,明显高于对照组患者的50.0%,差异有统计学意义(P<0.05);观察组患者治疗后1年生存率(75.0%)明显优于对照组(62.5%),差异有统计学意义(P<0.05);两组患者不良反应均较轻,差异无统计学意义(P>0.05)。结论采用西妥昔单抗联合调强适形放射治疗(IMRT)治疗局部晚期鼻咽癌疗效显著,有利于提高患者的生存率,值得临床推广和应用。Objective To investigate the clinical efficacy of cetuximab combined with IMRT in treatment of patients with locally advanced nasopharyngeal. Methods 100 patients with locally advanced na- sopharyngeal carcinoma were divided into two groups, including the observation group of 50 patients using IM- RT combined with eetuximab treatment and the control group of 50 patients treated with IMRT. Results Af- ter treatment, the total effective rate of the observation group was 92. 0%, significantly higher than the control patients 50. 0%, the difference was statistically significant （ P 〈 0.05 ）, and the observation group patients one year long-term efficacy were significantly better than the control group patients（75.0% and 62.5% , re- spectively）, and the differences were statistically significant （P 〈 0.05 ） , while the two groups of patients with adverse reactions were mild, and the difference was not statistically significant （ P 〉 0. 05 ）. Conclu- sion Cetuximab combined with IMRT in treatment of patients with locally advanced nasopharyngeal carci- noma has a very significant effect, which help to improve the survival rate of patients, and it is worthy of promotion and application.

关 键 词：西妥昔单抗 调强适形放射治疗 鼻咽肿瘤 临床疗效 

分 类 号：R739.63[医药卫生—肿瘤]